Update on microbicide research and development - Seeking new HIV prevention tools for women

European Journal of Medical Research

Volumn 16, Issue 1, 2011, Pages 1-6

  Mertenskoetter, T ^a   Kaptur, Paulina E ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

Antiretrovirals; HIV prevention; Microbicides; Pre exposure prophylaxis (PrEP); Vaginal gel; Vaginal ring

Indexed keywords

ANTIRETROVIRUS AGENT; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; MICROBICIDE; MIV 150; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONOXINOL 9; POLYANION; PRO 2000; SAVVY; SURFACTANT; TENOFOVIR; TENOFOVIR DISOPROXIL; TMC 278 LA; UNCLASSIFIED DRUG;

AFRICA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL INFECTION; GEL; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; VAGINA RING; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; INFECTION PREVENTION; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS;

EID: 79951503888     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-1-1     Document Type: Review

References (39)

1. AIDS epidemic update 2009. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009. UNAIDS/09.36E/JC1700E, November 2009.
2. Gouws E, Stanecki KA, Lyerla R, Ghys PD. The epidemiology of HIV infection among young people aged 15-24 years in southern Africa. AIDS. 2008 Dec; 22 Suppl 4: S5-16.
3. Chandran P, Kabir SN. Dual action microbicides: reappraisal of their roles in contraceptive research. Reprod Biomed Online. 2010 Jan; 20(1): 103-13.
4. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M; COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002 Sep 28; 360(9338): 971-7.
5. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008 Jan 23; 3(1): e1471.
6. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D; CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008 Jul 31; 359(5): 463-72.
7. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassini N, Palanee T, Dozier G, Maguire R, Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Dec 6; 372(9654): 1977-87.
8. Morris GC, Lacey CJN. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis. 2010 Feb; 23(1): 57-63.
9. Nuttall J. Microbicides in the prevention of HIV infection: current status and future directions. Drugs. 2010 Jul 9; 70(10): 1231-43.
10. Friend DR. Pharmaceutical development of microbicide drug products. Pharm Dev Technol. 2009 Dec 17; 1-20.
11. Romano J, Malcolm RK, Garg S, Rohan LC, Kaptur PE. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS. 2008 Sep; 3(5): 558-66.
12. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in Women. Sciencexpress. 2010 Jul 19; 1-13.
13. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr. 2010 Oct 1; 55(2): 161-9.
14. Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, Romano J. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses. 2010 Sep 21 {Epub ahead of print}.
15. Nel A, Kamupira M, Hetro C, Nuttall J, Romano J. Safety and pharmacokinetics trial of dapivirine matrix vaginal ring. 18th International AIDS Conference, Vienna, Austria, July 18-23, 2010, #PE0391.
16. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, Temmerman M, Verstraelen H, Van Bortel L, Weyers S, Mitchnick M. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009 May; 25(5): 1-6.
17. Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy HIV-negative women. AIDS. 2009 Jul 31; 23(12): 1531 8.
18. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, Romano J. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009 Aug 1; 51(4): 416-23.
19. Van't Klooster G, van der Geest R, Gille D. Parmacokinetics, tolerability and safety of multiple oral doses of TMC120 (R147681) in 32 healthy subjects. Tibotec Pharmaceuticals Ltd. Trial No. TIBO-0001-104, Report No. TMC120-C104-CRR, April 9, 2004.
20. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP. Protection of Rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 coreceptor. J Infect Dis. 2010 Sep 1; 202(5): 739-44. http://www.retroconference.org/2010/ Abstracts/39821.htm Accessed on September 28, 2010.
21. Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M. Efficacy of Carraguard®-based microbicides in vivo despite variable in vitro activity. PLoS One. 2008 Sep 8; 3(9): e3162.
22. Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol KM, Li J, Miller T, Robbiani M, Maguire RA, Buckheit RW Jr, Hartman TL, Phillips DM. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007 Jan; 34(1): 9-14.
23. Nonclinical Laboratory Studies: PC-1005 Gel (Carrageenan with Added MIV-150 and Zinc Salts). Population Council website. http://www.popcouncil.org/ projects/285-NonclinLabPC1005.asp. Accessed on September 27, 2010.
24. Nonclinical Laboratory Studies: Vaginal Rings Loaded with MIV-150. Population Council website. http://www.popcouncil.org/projects/286- NonclinLabMIV150Ring.asp. Accessed on September 27, 2010.
25. Nonclinical Laboratory Studies: Microbicide Formulation and Delivery. Population Council website. http://www.popcouncil.org/projects/285- NonclinLabPC1005.asp. Accessed on September 27, 2010.
26. Bagnarelli P, Menzo S, Manzin A, Giacca M, Varaldo PE, Clementi M. Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. J Med Virol. 1991 Jun; 34(2): 89-95.
27. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990 Jan 18; 322(3): 166-72.
28. Garg AB, Nuttall J, Romano J. The future of HIV microbicides: challenges and opportunities. Antiviral Chem Chemother. 2009; 19(4): 143-50.
29. Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, Tillman SN, van der Straten A. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2009 Nov 19. [Epub ahead of print] doi: 10.1007/s10461-009-9635x.
30. Nel AM, Lambert A, Isaacs M, Albertse M, Coetzee L. Daily monitored adherence as a possible adherence enabler in microbicide trials. Microbicides 2010 - Building Bridges in HIV Prevention, Pittsburgh, PA, USA, May 22-25, 2010, Abstract #58.
31. Schwanz JL, Rountree R, Kashuba A, Brache V, Creinin M, Poindexter A , Kearney, B. A multi-compartment, single and multiple dose pharmacokinetic study of the candidate vaginal microbicide 1% tenofovir gel. 5th IAS Conference of HIV, Pathogenesis, Treatemtn and Prevention, Cape Town, South Africa, July 19-22, 2009, Abstract No. LBPEC03.
32. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerabilityof tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20(4): 543-51.
33. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008 Nov; 8(11): 685-97.
34. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008; 11(2 Pt 1): 267-277.
35. Lete I, Doval JL, Perez-Campos E, et al. Factors affecting women's selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception 2007; 76:77-83.
36. Kamali A. What is new in HIV/AIDS research in developing countries? Trop Med Int Health. 2010 Aug; 15(8): 975-80.
37. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre-and postexposure prophylaxis. Clin Infect Dis. 2010 May 15; 50 Suppl 3: S96-101.
38. Underhill K, Operario D, Skeer MR, Mimiaga MJ, Mayer KH. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr. 2010 Sep 1; 55(1): 8-13.
39. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Nov 23. [Epub ahead of print].